Vonoprazan-based therapy forHelicobacter pylorieradication: experience and clinical evidence.
Stable suppression of gastric acid secretion is a crucial factor inHelicobacter pylorieradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, andH. pyloriinfection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use inH. pylorieradication. The latest literature and our clinical experience have shown that vonoprazan-based therapies have satisfactory eradication rates. Additionally, vonoprazan-based therapies are associated with similar rates of adverse events as standard triple therapies with conventional proton-pump inhibitors.
Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Yuko
Y
Akazawa
Fukuda Yutaka Surgery Clinic, Nagasaki, Japan.
Daisuke
D
Fukuda
Fukuda Yutaka Surgery Clinic, Nagasaki, Japan.
Yutaka
Y
Fukuda
H. pylori; P-CAB; PPI; TAK-438; Takecab; Vonoprazan; potassium-competitive acid blocker